An accurate determination of human epidermal growth factor receptor 2 (Her2) status in women with breast cancer is mandatory to identify patients who will benefit from trastuzumab-based therapy.
Pennacchia, I., Vecchio, F. M., Carbone, A., Arena, V., HER2 immunohistochemical assessment with A0485 polyclonal antibody: is it time to refine the scoring criteria for the "2+" category?, <<APPLIED IMMUNOHISTOCHEMISTRY AND MOLECULAR MORPHOLOGY>>, 2015; 23 (1): 31-35. [doi:10.1097/PAI.0000000000000047] [http://hdl.handle.net/10807/70983]
Autori: | |
Titolo: | HER2 immunohistochemical assessment with A0485 polyclonal antibody: is it time to refine the scoring criteria for the "2+" category? |
Digital Object Identifier (DOI): | http://dx.doi.org/10.1097/PAI.0000000000000047 |
Data di pubblicazione: | 2015 |
Abstract: | An accurate determination of human epidermal growth factor receptor 2 (Her2) status in women with breast cancer is mandatory to identify patients who will benefit from trastuzumab-based therapy. |
Lingua: | Inglese |
Rivista: | |
Citazione: | Pennacchia, I., Vecchio, F. M., Carbone, A., Arena, V., HER2 immunohistochemical assessment with A0485 polyclonal antibody: is it time to refine the scoring criteria for the "2+" category?, <<APPLIED IMMUNOHISTOCHEMISTRY AND MOLECULAR MORPHOLOGY>>, 2015; 23 (1): 31-35. [doi:10.1097/PAI.0000000000000047] [http://hdl.handle.net/10807/70983] |
Appare nelle tipologie: | Articolo in rivista, Nota a sentenza |
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.